COMP <GO>
CUVL vs CDTG // ENTERPRISE SCALE & MARKET CAP
Clinuvel Pharmaceuticals Limited (NASDAQ) VS. CDT Environmental Technology Investment Holdings Limited (NASDAQ) • 15-METRIC TALLY: CUVL 7
— CDTG 1
▲ ENTERPRISE SCALE & MARKET CAP LEADER: CUVL
LAST: $5.15 (+1.58%) • MKT CAP: $257.8M
market-cap
$257.8M
LAST: $0.94 (-7.84%) • MKT CAP: $2.8M
market-cap
$2.8M
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CUVL VS. CDTG)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CUVL | CDTG | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 81.20% | 41.50% | +39.70 | CUVL | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | -30.10% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | 9.7x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 10.51% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | 43.40% | -60.00% | +103.40 | CUVL | /operating-margins <GO> |
| Net Profit Margin | 37.80% | -55.90% | +93.70 | CUVL | /net-margins <GO> |
| Revenue Growth (YoY) | 5.50% | -38.80% | +44.30 | CUVL | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.66% | 0.00% | +0.66 | CUVL | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 0.38 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 3/9 | +3.00 | CUVL | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 37.7 | 39.3 | -1.65 | CDTG | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 10.3x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $257.8M | $2.8M | $255.0M | CUVL | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CUVL REV | CDTG REV | CUVL GROSS % | CDTG GROSS % | CUVL FCF | CDTG FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $61.1M | $18.2M | 81.2% | 41.5% | $27.1M | -$1.5M |
| FY 2024 | $57.9M | $29.8M | 81.5% | 37.8% | $20.1M | -$2.0M |
| FY 2023 | — | $34.2M | — | — | — | -$3.1M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CUVL // BETA —
CDTG // BETA —